NCT Number: NCT05736640
Osseointegrated Transdermal Femoral Amputation Prostheses
Femur amputated patients often suffer from several problems with conventional socket prosthesis. Some experience changes in gait, discomfort when sitting, altered skin conditions (infection, irritation, rashes, sweat), phantom pain or lack of stabilization between the prosthesis and the residual limb. Many have a low score on "health-related quality of life" questionnaires (HRQL).
Some femur amputated patients may be a candidate to osseointegrated prosthesis. Osseointegrated prosthesis is an implant, where the fixture is inserted into the femur canal and an abutment screw, on which the leg-prostheses is inserted, protrudes the skin. By this procedure the patient have a high score on HRQL and experience fewer problems. They have improved gait, reduced discomfort when sitting, increased prosthetic use, and experience fewer skin and pain problems.
Femur amputee patients formerly mobilized on socket prosthesis have a reduced bone mineral density in the affected femur and pelvis.
The Phd-theses compromise of three studies. The aim of the first study is to follow patients with oosseointegrated prosthesis before and after surgery with DXA-scans to monitor the BMD. In the second study patients will be randomised to receive medical treatment with an RANKL-inhibitor, approved for treatment of osteoporosis, and monitored with DXA, microdialysis and radiostereometry. Depending on the DXA-results patients in the third study may receive fast track rehabilitation.
The hypothesis is that patients with osseointegrated prosthesis will have an increased BMD after surgery, 2 years follow up. Patients receiving RANKL inhibitor will have increased BMD, stability of the prosthesis, and some receive fast-track rehabilitation due to high BMD.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age between 18-70 years
- Scheduled for OI-implant surgery
- Body mass index <30
- Female patients of childbearing age must produce a negative pregnancy test and use effective contraception
- informed consent
Exclusion criteria
- Diabetes with complication
- Atherosclerosis
- Smoking
- Drug abuse
- Treatment with NSAID or cytostatic
- Active cancer
- Liver or kidney insufficiency
- Dementia
- Hip flexion contracture on the affected side >10 degrees
- Body weight >100 kg
- Hypocalcaemia
- Contraindications to denosumab
Treatment and study plan
Placebo
DrugPrimary outcomes
-
change in periprosthetic bone mineral density
Time frame: 30 months po
Sponsors and collaborators
Lead sponsor
University of Aarhus
Other
Registry information
Official study title
The Effect of Denosumab on Periprosthetic Bone Mineral Density in Six Transfemoral Amputees Treated With Osseointegrated Implants: The Observations From a Terminated Randomized Controlled Trial
Important dates
- Study start
- 2013
- Primary completion
- 2016
- Study completion
- 2016
- First posted
- Feb 21, 2023
- Registry last updated
- Apr 21, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Fish Oil for Cognitive Function, Sleep Quality, and Bone Density
NCT06614374
Bone Mineral Density, Cognition Disorders
Jinhua, Zhejiang, China
View Trial DetailsBone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
NCT02355340
Bone Mineral Density, Childhood Cancer Survivors
Boston, Massachusetts, United States
View Trial DetailsHigh Dose Vitamin D Supplementation in Children With Sickle Cell Disease
NCT06274203
Anemia, Anemia, Hemolytic
Zagazig, Sharqia Province, Egypt
View Trial DetailsReference Curve on Bone Mineral Density in Men
NCT03400982
Bone Mineral Density, Grip Strength
Amiens, France
View Trial Details